This information is intended for use by health professionals

1. Name of the medicinal product

SUBCUVIA 160 g/l Solution for Injection

2. Qualitative and quantitative composition

Human Normal Immunoglobulin

1 l solution contains:

human protein 160 g

(of which at least 90% are immunoglobulin G)

Distribution of IgG subclasses:

IgG1 45-75%

IgG2 20-45%

IgG3 3-10%

IgG4 2-8%

Maximum IgA content:

4.8 g/l of total protein

Excipient with known effects:

This medicinal product contains 1.4 mg sodium per ml.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Solution for subcutaneous or intramuscular administration.

4. Clinical particulars
4.1 Therapeutic indications

Replacement therapy in adults, children and adolescents (0-18) in:

• Primary immunodeficiency syndromes with impaired antibody production (see section 4.4),

• Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated.

• Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients

• Hypogammaglobulinaemia in patients pre- and post- allogenic haematopoietic stem cell transplant (HSCT).

4.2 Posology and method of administration

Replacement therapy

Treatment should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency.

The dosage may need to be individualised for each patient dependent on the pharmacokinetic and clinical response. The following dosage regimens are given as a guideline.

Adults and elderly:

The dosage should be adjusted to maintain trough level of at least 4-6 g/L of circulating IgG.

The dosage regimen using the subcutaneous route should achieve a sustained level of IgG (measured before the next infusion). A loading dose of at least 0.2-0.5 g/kg given over the course of one week (0.1 – 0.15 g/kg bodyweight on any given day) may be required. After steady state IgG levels have been attained, maintenance doses are administered at repeated intervals to reach a cumulative monthly dose of the order of 0.4-0.8 g/kg.

Trough levels should be measured in order to adjust the dose and dosage interval.

SUBCUVIA may also be injected by the intramuscular route. In such cases, the cumulative monthly dose should be divided up into weekly or bi-weekly applications, in order to keep the injected volume low. To further minimize the discomfort for the patient, each single dosage may need to be injected at different anatomic sites.


Administration of Subcuvia to children should use the same dosage recommendation as stated above for adults.

Method of administration

Human normal immunoglobulin is administered via the subcutaneous or intramuscular route.

SUBCUVIA should be administered via the subcutaneous route. In exceptional cases, where subcutaneous administration is not possible SUBCUVIA can be given intramuscularly.

Subcutaneous infusion for home treatment should be initiated by a physician experienced in the guidance of patients for home treatment. The patient will be instructed in the use of a syringe driver, infusion techniques, the keeping of a treatment diary and measures to be taken in case of severe adverse events.

It is recommended to use an initial speed of 10 ml/h/pump.

The infusion speed can be increased by 1 ml/h/pump every subsequent infusion. The recommended maximum speed is 20 ml/h/pump. More than one pump can be used simultaneously. The infusion site should be changed every 5-15 ml.

Intramuscular injection must be given by a physician or nurse.

4.3 Contraindications

Hypersensitivity to any of the components.

SUBCUVIA must not be given intravenously.

SUBCUVIA must not be administered intramuscularly in cases of severe thrombocytopenia and in other disorders of haemostasis.

4.4 Special warnings and precautions for use

If SUBCUVIA is accidentally administered into a blood vessel, patients could develop shock. Therefore, it must be ensured that SUBCUVIA is not administered into a blood vessel.

The recommended infusion rate stated under “4.2 Method of Administration” should be adhered to. Patients should be closely monitored and carefully be observed for any adverse events throughout the infusion period.

Patients receiving treatment at home, and/or their guardian must be trained to detect the early signs of hypotensive reactions that may seldom occur. Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. If severe anaphylactoid reactions do occur, standard medical treatment should be implemented and the patient or guardian should contact a doctor immediately.

Certain adverse reactions may occur more frequently in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when treatment has been stopped for more than eight weeks.

True hypersensitivity reactions are rare. They can particularly occur in very rare cases of IgA deficiency with anti-IgA antibodies and these patients should be treated with caution.

Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.

Potential complications can often be avoided by ensuring that:

• patients are not sensitive to human normal immunoglobulin by first injecting the product slowly (see 4.2)

• patients are carefully monitored for any symptoms throughout the infusion period. In particular, patients naïve to human normal immunoglobulin, patients switched from an alternative product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.

Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medical treatment should be administered.


Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins. Patients should be sufficiently hydrated before use of immunoglobulins. Caution should be exercised in patients with preexisting risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilization, severely hypovolemic patients, patients with diseases which increase blood viscosity).

Patients should be informed about first symptoms of thromboembolic events including shortness of breath, pain and swelling of a limb, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms.

Aseptic Meningitis Syndrome (AMS)

Aseptic meningitis syndrome has been reported to occur in association with immunoglobulin treatment; the symptoms usually begin within several hours to 2 days following treatment. Discontinuation of immunoglobulin treatment may result in remission of AMS within several days without sequelae.

Patients should be informed about first symptoms which encompass severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting.

Important information about some of the ingredients of Subcuvia

In a patient of 75 kg bodyweight, the maximal daily dose of 11.25 g IgG (70 ml SUBCUVIA) contains 98 mg (4.3 mmol) of sodium. The sodium content of SUBCUVIA should be taken into account in patients on a controlled sodium diet.

SUBCUVIA is made from human plasma.

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV.

The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.

Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased red blood cell turnover (e.g., haemolytic anaemia).

There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.

It is strongly recommended that every time that SUBCUVIA is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

Interference with serological testing:

After injection of immunoglobulin the transitory rise in the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.

Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell antibodies, for example the antiglobulin test (Coombs test), or other laboratory tests, e.g. reticulocyte count and haptoglobulin test.

Administration of SUBCUVIA can lead to false positive readings in assays that depend on detection of beta-D-glucans for diagnosis of fungal infections; this may persist during the weeks following infusion of the product.

4.5 Interaction with other medicinal products and other forms of interaction

Live attenuated virus vaccines

Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year.

Therefore patients receiving measles vaccine should have their antibody status checked.

4.6 Fertility, pregnancy and lactation

The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus and the neonate are to be expected.

Continued treatment of the pregnant woman is important to ensure that the neonate is born with appropriate passive immunity.

See section 4.4 for information on Parvovirus B19 infection.

4.7 Effects on ability to drive and use machines

The ability to drive and operate machines may be impaired by some adverse reactions associated with SUBCUVIA, such as dizziness, nausea, and/or tremor. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.

4.8 Undesirable effects

Summary of the safety profile

Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, dizziness, hyperhidrosis, pallor, paraesthesia, tachycardia, arthralgia, low blood pressure and moderate low back pain may occur occasionally.

Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.

Local reactions at infusion site: swelling, soreness, redness, induration, local heat, itching, bruising and rash may frequently occur.

For safety information with respect to transmissible agents, see section 4.4.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).

The adverse reactions presented in this section have been identified from three clinical trials and from post-marketing experience with Subcuvia.

Frequencies have been evaluated according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Frequency of Adverse Reactions (ADRs) with SUBCUVIA

MedDRA System Organ Class (SOC)

Adverse reaction



Anaphylactic shock

Anaphylactic/Anaphylactoid reactions


Not known*









Not known*



Not known*


Peripheral coldness


Hypotension, Hypertension Flushing, Pallor

Not known*



Not known*




Abdominal pain



Paresthesia oral

Not known*







Swelling face

Rash maculo-papular

Dermatitis allergic


Not known*


Musculoskeletal stiffness (including Chest discomfort)





Back pain

Not known*


Injection site hemorrhage

Injection site pain

Injection site hematoma

Injection site erythema



Injection site swelling

Injection site pruritus



Feeling hot


Injection site rash




Injection site reaction

Injection site urticaria

Injection site induration

Injection site warmth

Not known*


Alanine aminotransferase increased


Heart rate increased


* These ADRs have been reported from post marketing sources

Paediatric population

Frequency, type and severity of adverse reactions in children are the same as in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

4.9 Overdose

Consequences of an overdose are not known.

5. Pharmacological properties

SUBCUVIA is a liquid immunoglobulin concentrate for subcutaneous administration, which is manufactured from pooled human plasma.

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for extravascular administration. ATC code: J06BA01.

Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.

Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donations. It has a distribution of immunglobulin G subclasses closely proportional to that in native human plasma.

Adequate doses of this medicinal product may restore abnormally low immunoglobulin G levels to the normal range.

5.2 Pharmacokinetic properties

With subcutaneous administration of human normal immunoglobulin, peak levels are achieved in the recipient's circulation after a delay of about 4 days.

Data from clinical trials show that trough levels of 7,24-7,86 g/l can be maintained by dosing regimens of 1,25 ml (0,2 g)/kg bw administered at intervals of 2 weeks.

The half-life of total IgG calculated in patients with hypo- or agammaglobulinemia after subcutaneous administration of SUBCUVIA was calculated to be approximately 40 days.

With intramuscular administration, human normal immunoglobulin is bioavailable in the recipient's circulation after a delay of 2-3 days.

IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.

5.3 Preclinical safety data

Single dose toxicity studies demonstrate that the doses several times higher than the maximum recommended human dose had no toxic effects on laboratory animals.

Repeated dose toxicity testing in animals is impracticable due to interference with developing antibodies to heterologous protein.

Since human proteins have not been seen to cause tumorigenic or mutagenic effects, experimental studies particularly in a heterologous species are not considered necessary.

6. Pharmaceutical particulars
6.1 List of excipients


Sodium chloride

Water for Injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

30 months

Once opened: use immediately

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

During shelf life, the product may be stored at room temperature (not more than 25°C) for up to 3 months. The date of transfer to room temperature and the end of the 3 month period should be recorded on the outer carton. Once the product is stored at room temperature it must not be returned to the refrigerator and must be discarded, if not used by the end of the 3 month period.

Do not freeze.

Keep the container in the outer carton in order to protect from light.

Keep out of the reach and sight of children.

6.5 Nature and contents of container

The product is supplied in vials made of glass of hydrolytic type I that are closed with bromobutyl rubber stoppers.

SUBCUVIA is available in packages containing either:

1 vial with 5 ml solution for injection/infusion,

20 vials with 5 ml solution for injection/infusion each, or

1 vial with 10 ml solution for injection/infusion.

20 vials with 10 ml solution for injection/infusion

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The product should be brought to room or body temperature before use.

Do not use heating devices to warm up the product.

The liquid preparation is clear and pale yellow to light brown; during storage it may show formation of slight turbidity or a small amount of particulate matter.

Solutions that are cloudy or have deposits should not be used.

Entered vials must not be reused.

After opening of the vial the product must be used immediately.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Baxalta Innovations GmbH, Industriestrasse 67, A-1221 Vienna, Austria

8. Marketing authorisation number(s)

PL 34078/0010

9. Date of first authorisation/renewal of the authorisation

First Authorisation: 05/11/2003

10. Date of revision of the text

March 2018